Illumina, Inc. $ILMN Shares Purchased by Exchange Traded Concepts LLC

Key Points

• Exchange Traded Concepts LLC increased its stake in Illumina, Inc. by 2.0% during Q2, bringing its total ownership to approximately 225,029 shares valued at $21.47 million.
• Several institutional investors have also adjusted their holdings in Illumina, with significant percentage increases from firms like Rise Advisors LLC and Rakuten Securities Inc..
• Following recent research reports, Illumina's stock rating has been downgraded from "buy" to "hold" by multiple analysts, with a current consensus rating of "Hold" and an average target price of $123.06.

Exchange Traded Concepts LLC increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 225,029 shares of the life sciences company's stock after buying an additional 4,338 shares during the period. Exchange Traded Concepts LLC owned about 0.14% of Illumina worth $21,470,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. Corvex Management LP increased its stake in Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company's stock worth $303,841,000 after buying an additional 2,129,449 shares during the period. AQR Capital Management LLC increased its position in shares of Illumina by 361.7% in the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company's stock worth $165,484,000 after purchasing an additional 1,662,093 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Illumina by 11,714.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company's stock worth $92,184,000 after purchasing an additional 1,152,048 shares during the last quarter. Brown Advisory Inc. increased its position in shares of Illumina by 52.1% in the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock worth $230,818,000 after purchasing an additional 996,589 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Illumina by 2,057.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock worth $73,174,000 after purchasing an additional 879,533 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Performance

Illumina stock traded down $0.28 during midday trading on Friday, reaching $102.75. 3,621,712 shares of the stock traded hands, compared to its average volume of 1,309,960. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The firm has a fifty day moving average price of $99.78 and a two-hundred day moving average price of $89.04. The firm has a market cap of $15.79 billion, a price-to-earnings ratio of 13.01, a PEG ratio of 2.32 and a beta of 1.43. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina's revenue was down 4.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ILMN shares. Barclays boosted their target price on shares of Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a research report on Friday, August 1st. Robert W. Baird boosted their target price on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research report on Monday, July 28th. Royal Bank Of Canada set a $124.00 price objective on shares of Illumina in a research report on Tuesday, September 2nd. Canaccord Genuity Group boosted their price objective on shares of Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research report on Friday, August 1st. Finally, Daiwa Capital Markets downgraded shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Illumina currently has a consensus rating of "Hold" and a consensus price target of $123.06.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.